GenMark Diagnostics, Inc. (NASDAQ:GNMK) Director Michael Kagnoff bought 2,500 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was purchased at an average cost of $9.15 per share, with a total value of $22,875.00. Following the completion of the transaction, the director now directly owns 44,413 shares of the company’s stock, valued at $406,378.95. The transaction was disclosed in a filing with the SEC, which is available through this link.

GenMark Diagnostics, Inc. (NASDAQ:GNMK) opened at 9.43 on Tuesday. The stock’s market capitalization is $515.51 million. GenMark Diagnostics, Inc. has a 12 month low of $8.03 and a 12 month high of $13.67. The stock has a 50 day moving average price of $10.29 and a 200 day moving average price of $11.98.

GenMark Diagnostics (NASDAQ:GNMK) last posted its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.32) by $0.05. The company had revenue of $12.36 million during the quarter, compared to analysts’ expectations of $12.44 million. GenMark Diagnostics had a negative return on equity of 109.89% and a negative net margin of 111.96%. The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.30) earnings per share. On average, equities research analysts forecast that GenMark Diagnostics, Inc. will post ($1.06) earnings per share for the current fiscal year.

WARNING: “GenMark Diagnostics, Inc. (GNMK) Director Michael Kagnoff Buys 2,500 Shares of Stock” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/09/12/genmark-diagnostics-inc-gnmk-director-michael-kagnoff-buys-2500-shares-of-stock.html.

A number of analysts have issued reports on the company. BTIG Research reissued a “buy” rating and issued a $13.00 target price on shares of GenMark Diagnostics in a research report on Thursday, August 31st. Needham & Company LLC raised their target price on GenMark Diagnostics from $16.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reissued a “buy” rating and issued a $17.00 target price on shares of GenMark Diagnostics in a research report on Monday, June 12th. Cowen and Company reissued an “outperform” rating and issued a $17.00 target price on shares of GenMark Diagnostics in a research report on Wednesday, August 2nd. Finally, ValuEngine raised GenMark Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and four have issued a buy rating to the company. GenMark Diagnostics has an average rating of “Hold” and a consensus price target of $15.00.

Several large investors have recently bought and sold shares of GNMK. Teachers Advisors LLC increased its stake in shares of GenMark Diagnostics by 6.1% in the 4th quarter. Teachers Advisors LLC now owns 98,220 shares of the medical equipment provider’s stock worth $1,202,000 after purchasing an additional 5,652 shares in the last quarter. Nationwide Fund Advisors increased its stake in shares of GenMark Diagnostics by 3.9% in the 1st quarter. Nationwide Fund Advisors now owns 25,936 shares of the medical equipment provider’s stock worth $332,000 after purchasing an additional 981 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of GenMark Diagnostics by 3.3% in the 1st quarter. Bank of New York Mellon Corp now owns 204,928 shares of the medical equipment provider’s stock worth $2,627,000 after purchasing an additional 6,482 shares in the last quarter. TD Asset Management Inc. increased its stake in shares of GenMark Diagnostics by 3.1% in the 1st quarter. TD Asset Management Inc. now owns 102,074 shares of the medical equipment provider’s stock worth $1,309,000 after purchasing an additional 3,074 shares in the last quarter. Finally, Ameriprise Financial Inc. purchased a new stake in shares of GenMark Diagnostics in the 1st quarter worth $435,000.

About GenMark Diagnostics

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

Receive News & Stock Ratings for GenMark Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GenMark Diagnostics Inc. and related stocks with our FREE daily email newsletter.